Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics ...

6 Based on these findings, recognizing diastolic dysfunction in boys with DMD may allow patients at risk of earlier cardiomyopathic progression to be identified sooner. Findings from a recent ...

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

A 12-year-old boy with a severe form of muscular dystrophy has said it is "cruel" that a new drug is not being made available ...

The results provided no evidence that ezutromid is having a meaningful effect on slowing DMD progression.” Summit will now redirect its resources to focus on antibiotic pipeline starting phase 3 ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

"The company also plans to collaborate with academic institutions to collect additional natural history and magnetic resonance imaging data on DMD progression during 2015," according to Sanyal ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Diastolic Dysfunction May Predict Rapid Cardiomyopathy Progression in Duchenne Muscular Dystrophy Previous echocardiography studies have suggested that diastolic dysfunction may precede systolic ...